The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said ...

The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

Tirzepatide is also the compound in the diabetes drug Mounjaro. Advertising Even before the FDA approval, some doctors have ...

The weight loss drug Zepbound has become the first prescription medication approved to treat ... The American Academy of ...

The FDA approval for sleep apnea is ... That equates to 45 to 50 pounds of weight loss, on average, over a year, Lilly said. Patients on the drug also saw reductions in blood pressure and ...

Sally Seymour of the FDA's Center for Drug Evaluation and Research ... a move that would have to be approved by the incoming Trump administration. Rapid weight loss has been a hallmark of ...

The FDA on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug ...